Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma

Wei Chung Hsu, Sue Ching Chan, Lai Lei Ting, Na Na Chung, Po Ming Wang, K. S Kung Shih Ying, Jeng Shiann Shin, Che Jen Chao, Gau De Lin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: To evaluate the effectiveness of three-dimensional conformal radiotherapy and thalidomide in the treatment of advanced hepatocellular carcinoma. Methods: Between 1999 and 2003, 121 patients (mean age, 54.4 ± 12.4 years; range, 20-81 years) with advanced hepatocellular carcinoma received three-dimensional conformal radiotherapy and thalidomide. Radiation was delivered in 1.5 Gy fractions twice daily for 5 days a week, for a total dose of 45-75 Gy. Mean treatment volume was 429.52 ± 408.50 cm3 (range, 26.89-2284.82 cm3). Thalidomide was given concomitantly: 200 mg/day in 109 patients, 300 mg/ day in 8 patients and 400 mg/day in 4 patients. Treatment responses0, survival rates and factors affecting survival were analyzed. Results: Treatment responses were observed in 61% of the patients. Liver cirrhosis (P = 0.001) and tumor size (P = 0.001) significantly affected the tumor responses. Overall survival at 6, 12 and 24 months was 84.8, 60.0 and 44.6%, respectively. On univariate analysis, liver cirrhosis (P = 0.003), Karnofsky performance status (P = 0.007), tumor size (P < 0.001), portal vein tumor thrombosis (P < 0.001) and alpha-fetoprotein level (P = 0.003) were shown to significantly affect survival. On multivariate analysis, only thrombosis (P = 0.039) and alpha-fetoprotein level (P = 0.006) were shown to be factors affecting survival. Conclusions: Three-dimensional conformal radiotherapy with thalidomide seems to be effective in the treatment of advanced hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)93-99
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume36
Issue number2
DOIs
Publication statusPublished - Feb 1 2006
Externally publishedYes

Fingerprint

Conformal Radiotherapy
Thalidomide
Hepatocellular Carcinoma
Survival
alpha-Fetoproteins
Liver Cirrhosis
Neoplasms
Thrombosis
Therapeutics
Karnofsky Performance Status
Portal Vein
Multivariate Analysis
Survival Rate
Radiation

Keywords

  • Conformal radiotherapy
  • Hepatocellular carcinoma
  • Thalidomide

ASJC Scopus subject areas

  • Oncology

Cite this

Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. / Hsu, Wei Chung; Chan, Sue Ching; Ting, Lai Lei; Chung, Na Na; Wang, Po Ming; Ying, K. S Kung Shih; Shin, Jeng Shiann; Chao, Che Jen; Lin, Gau De.

In: Japanese Journal of Clinical Oncology, Vol. 36, No. 2, 01.02.2006, p. 93-99.

Research output: Contribution to journalArticle

Hsu, Wei Chung ; Chan, Sue Ching ; Ting, Lai Lei ; Chung, Na Na ; Wang, Po Ming ; Ying, K. S Kung Shih ; Shin, Jeng Shiann ; Chao, Che Jen ; Lin, Gau De. / Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. In: Japanese Journal of Clinical Oncology. 2006 ; Vol. 36, No. 2. pp. 93-99.
@article{0ebe17eb4d1943a8829a8d9328ebbf77,
title = "Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma",
abstract = "Purpose: To evaluate the effectiveness of three-dimensional conformal radiotherapy and thalidomide in the treatment of advanced hepatocellular carcinoma. Methods: Between 1999 and 2003, 121 patients (mean age, 54.4 ± 12.4 years; range, 20-81 years) with advanced hepatocellular carcinoma received three-dimensional conformal radiotherapy and thalidomide. Radiation was delivered in 1.5 Gy fractions twice daily for 5 days a week, for a total dose of 45-75 Gy. Mean treatment volume was 429.52 ± 408.50 cm3 (range, 26.89-2284.82 cm3). Thalidomide was given concomitantly: 200 mg/day in 109 patients, 300 mg/ day in 8 patients and 400 mg/day in 4 patients. Treatment responses0, survival rates and factors affecting survival were analyzed. Results: Treatment responses were observed in 61{\%} of the patients. Liver cirrhosis (P = 0.001) and tumor size (P = 0.001) significantly affected the tumor responses. Overall survival at 6, 12 and 24 months was 84.8, 60.0 and 44.6{\%}, respectively. On univariate analysis, liver cirrhosis (P = 0.003), Karnofsky performance status (P = 0.007), tumor size (P < 0.001), portal vein tumor thrombosis (P < 0.001) and alpha-fetoprotein level (P = 0.003) were shown to significantly affect survival. On multivariate analysis, only thrombosis (P = 0.039) and alpha-fetoprotein level (P = 0.006) were shown to be factors affecting survival. Conclusions: Three-dimensional conformal radiotherapy with thalidomide seems to be effective in the treatment of advanced hepatocellular carcinoma.",
keywords = "Conformal radiotherapy, Hepatocellular carcinoma, Thalidomide",
author = "Hsu, {Wei Chung} and Chan, {Sue Ching} and Ting, {Lai Lei} and Chung, {Na Na} and Wang, {Po Ming} and Ying, {K. S Kung Shih} and Shin, {Jeng Shiann} and Chao, {Che Jen} and Lin, {Gau De}",
year = "2006",
month = "2",
day = "1",
doi = "10.1093/jjco/hyi242",
language = "English",
volume = "36",
pages = "93--99",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma

AU - Hsu, Wei Chung

AU - Chan, Sue Ching

AU - Ting, Lai Lei

AU - Chung, Na Na

AU - Wang, Po Ming

AU - Ying, K. S Kung Shih

AU - Shin, Jeng Shiann

AU - Chao, Che Jen

AU - Lin, Gau De

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Purpose: To evaluate the effectiveness of three-dimensional conformal radiotherapy and thalidomide in the treatment of advanced hepatocellular carcinoma. Methods: Between 1999 and 2003, 121 patients (mean age, 54.4 ± 12.4 years; range, 20-81 years) with advanced hepatocellular carcinoma received three-dimensional conformal radiotherapy and thalidomide. Radiation was delivered in 1.5 Gy fractions twice daily for 5 days a week, for a total dose of 45-75 Gy. Mean treatment volume was 429.52 ± 408.50 cm3 (range, 26.89-2284.82 cm3). Thalidomide was given concomitantly: 200 mg/day in 109 patients, 300 mg/ day in 8 patients and 400 mg/day in 4 patients. Treatment responses0, survival rates and factors affecting survival were analyzed. Results: Treatment responses were observed in 61% of the patients. Liver cirrhosis (P = 0.001) and tumor size (P = 0.001) significantly affected the tumor responses. Overall survival at 6, 12 and 24 months was 84.8, 60.0 and 44.6%, respectively. On univariate analysis, liver cirrhosis (P = 0.003), Karnofsky performance status (P = 0.007), tumor size (P < 0.001), portal vein tumor thrombosis (P < 0.001) and alpha-fetoprotein level (P = 0.003) were shown to significantly affect survival. On multivariate analysis, only thrombosis (P = 0.039) and alpha-fetoprotein level (P = 0.006) were shown to be factors affecting survival. Conclusions: Three-dimensional conformal radiotherapy with thalidomide seems to be effective in the treatment of advanced hepatocellular carcinoma.

AB - Purpose: To evaluate the effectiveness of three-dimensional conformal radiotherapy and thalidomide in the treatment of advanced hepatocellular carcinoma. Methods: Between 1999 and 2003, 121 patients (mean age, 54.4 ± 12.4 years; range, 20-81 years) with advanced hepatocellular carcinoma received three-dimensional conformal radiotherapy and thalidomide. Radiation was delivered in 1.5 Gy fractions twice daily for 5 days a week, for a total dose of 45-75 Gy. Mean treatment volume was 429.52 ± 408.50 cm3 (range, 26.89-2284.82 cm3). Thalidomide was given concomitantly: 200 mg/day in 109 patients, 300 mg/ day in 8 patients and 400 mg/day in 4 patients. Treatment responses0, survival rates and factors affecting survival were analyzed. Results: Treatment responses were observed in 61% of the patients. Liver cirrhosis (P = 0.001) and tumor size (P = 0.001) significantly affected the tumor responses. Overall survival at 6, 12 and 24 months was 84.8, 60.0 and 44.6%, respectively. On univariate analysis, liver cirrhosis (P = 0.003), Karnofsky performance status (P = 0.007), tumor size (P < 0.001), portal vein tumor thrombosis (P < 0.001) and alpha-fetoprotein level (P = 0.003) were shown to significantly affect survival. On multivariate analysis, only thrombosis (P = 0.039) and alpha-fetoprotein level (P = 0.006) were shown to be factors affecting survival. Conclusions: Three-dimensional conformal radiotherapy with thalidomide seems to be effective in the treatment of advanced hepatocellular carcinoma.

KW - Conformal radiotherapy

KW - Hepatocellular carcinoma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=33645142946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645142946&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyi242

DO - 10.1093/jjco/hyi242

M3 - Article

C2 - 16517834

AN - SCOPUS:33645142946

VL - 36

SP - 93

EP - 99

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -